News

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th

The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Deal or no deal, mere talks between Astrazeneca and Bristol-Myers point to one of the global pharma industry’s biggest themes.

The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.

SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

AbbVie (ABBV) reported another "strong" quarter operationally, with investor attention increasingly

IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]

AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

AbbVie Inc (ABBV) beats expectations with 10.2% revenue growth, raises full-year guidance, and showcases promising pipeline developments despite Humira's decline.

Moby summary of AbbVie Inc.'s Q2 2026 earnings call

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution

Earnings Data Deluge

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p

Despite some mid-week turbulence, we're trading fairly even with where we were as of mid-day Monday.

Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.

The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Find insight on Sanofi, Haleon, Cochlear and more in the latest Market Talks covering the health care sector.

The benchmark US stock measures were tracking in the green before the open Friday as Amazon's (AMZN)

Asking for a Trend Host Josh Lipton previews what investors should be on the lookout for on Friday, July 31, including earnings from energy giants Exxon (XOM), Chevron (CVX), and biopharma AbbVie (ABBV) as well as the latest read on consumer sentiment.

Asking for a Trend Host Josh Lipton previews what investors should be on the lookout for on Friday, August 1, including earnings from energy giants Exxon (XOM), Chevron (CVX), and biopharma AbbVie (ABBV) as well as the latest read on consumer sentiment.

Rinvoq, Comirnaty and Opzelura have all received their own EC approvals this week.